Prostate Cancer Clinical Trials in Dallas, Texas
20 recruitingDallas, Texas
Showing 1–20 of 20 trials
Recruiting
Phase 3
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
Prostate CancerCryotherapyProstate Cancer Recurrent+3 more
Clarity Pharmaceuticals Ltd220 enrolled28 locationsNCT06970847
Recruiting
Phase 3
Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
Prostate Cancer
yair lotan608 enrolled1 locationNCT02064673
Recruiting
Phase 3
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Prostate CancerProstatic Neoplasms
Clarity Pharmaceuticals Ltd383 enrolled27 locationsNCT06056830
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled274 locationsNCT06925737
Recruiting
Phase 1Phase 2
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Ovarian CancerEndometrial CancerProstate Cancer+5 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 3
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Prostate CancerCancer of the ProstateHormone Sensitive Prostate Cancer+1 more
Pfizer1,000 enrolled188 locationsNCT07028853
Recruiting
Phase 2
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Prostate CancerProstate Adenocarcinoma
University of Chicago90 enrolled2 locationsNCT05726292
Recruiting
Phase 2
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Prostate Cancer
Debiopharm International SA66 enrolled37 locationsNCT06395753
Recruiting
DESTINY-PANTUMOUR04
Liver CancerEsophageal CancerPancreatic Cancer+24 more
AstraZeneca100 enrolled15 locationsNCT07124000
Recruiting
Phase 1
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Breast CancerOvarian CancerProstate Cancer+8 more
Clasp Therapeutics, Inc.90 enrolled21 locationsNCT06778863
Recruiting
Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Prostate Cancer
Astellas Pharma Global Development, Inc.174 enrolled25 locationsNCT04729114
Recruiting
Phase 1
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
Prostate CancerMetastatic Castration-resistant Prostate Cancer
Janux Therapeutics272 enrolled35 locationsNCT05519449
Recruiting
Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1
Prostate Cancer
University of Texas Southwestern Medical Center25 enrolled1 locationNCT06353321
Recruiting
Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Prostate Cancer
Astellas Pharma Global Development, Inc.900 enrolled241 locationsNCT02960022
Recruiting
Phase 2
Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)
Prostate Cancer
University of Texas Southwestern Medical Center68 enrolled1 locationNCT07313241
Recruiting
Phase 1Phase 2
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
Prostate CancerNeoplasmsNeoplasms by Site+7 more
Pathos AI, Inc.252 enrolled10 locationsNCT06785636
Recruiting
Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
Prostate Cancer
University of Texas Southwestern Medical Center291 enrolled1 locationNCT03769766
Recruiting
Phase 4
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Prostate Cancer
Novartis Pharmaceuticals700 enrolled54 locationsNCT05803941
Recruiting
Outcomes of Focal Ablation for Prostate Cancer
Prostate Cancer
University of Texas Southwestern Medical Center225 enrolled1 locationNCT05478694
Recruiting
Customized TULSA-PRO Ablation Registry
Prostate CancerProstate AdenocarcinomaBenign Prostatic Hyperplasia
Profound Medical Inc.1,000 enrolled5 locationsNCT05001477